|
MED9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.99630001207885E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.70110000530244E-08 |
| Normal-vs-Stage2 |
7.785700E-02 |
| Normal-vs-Stage3 |
1.48589999970916E-07 |
| Normal-vs-Stage4 |
2.7346999997846E-08 |
| Stage1-vs-Stage2 |
1.395490E-03 |
| Stage1-vs-Stage3 |
4.535600E-01 |
| Stage1-vs-Stage4 |
2.327600E-02 |
| Stage2-vs-Stage3 |
7.448600E-04 |
| Stage2-vs-Stage4 |
1.69968999998993E-05 |
| Stage3-vs-Stage4 |
1.270240E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.1420999701528E-09 |
| Normal-vs-AfricanAmerican |
1.226040E-02 |
| Normal-vs-Asian |
8.13510000474693E-08 |
| Caucasian-vs-AfricanAmerican |
5.537000E-01 |
| Caucasian-vs-Asian |
1.862970E-01 |
| AfricanAmerican-vs-Asian |
2.674600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.86210000050625E-07 |
| Normal-vs-Female |
1.54629999915556E-08 |
| Male-vs-Female |
6.968400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.94520000007925E-07 |
| Normal-vs-Age(41-60Yrs) |
4.65730000009934E-07 |
| Normal-vs-Age(61-80Yrs) |
1.955760E-04 |
| Normal-vs-Age(81-100Yrs) |
2.915400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.472400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.767760E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.916200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.516800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.439000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.768580E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.969000E-04 |
| Classical-VS-Follicular |
9.71250000000312E-05 |
| Classical-VS-Other |
6.535400E-01 |
| Classical-VS-Normal |
1.89630000591023E-09 |
| Tall-VS-Follicular |
1.81829999945649E-08 |
| Tall-VS-Other |
1.485400E-01 |
| Tall-VS-Normal |
1.63340008185742E-10 |
| Follicular-VS-Other |
4.251400E-01 |
| Follicular-VS-Normal |
2.090500E-02 |
| Other-VS-Normal |
9.220100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.88599999999939E-05 |
| Normal-vs-N1 |
9.52000001053221E-09 |
| N0-vs-N1 |
6.19069999999722E-05 |
|
|
